

BAXTER INTERNATIONAL INC.
Key Product Line Sales
Periods Ending December 31, 2009 and 2008
(unaudited)
(\$ in millions)

	Q4 2009	Q4 2008	% Growth @ Actual Rates	% Growth @ Constant Rates	YTD 2009	YTD 2008	% Growth @ Actual Rates	% Growth @ Constant Rates
BioScience								
Recombinants	\$564	\$506	11%	6%	\$2,058	\$1,966	5%	9%
Plasma Proteins	380	330	15%	10%	1,338	1,219	10%	17%
Antibody Therapy	351	309	14%	10%	1,368	1,217	12%	14%
Regenerative Medicine	125	101	24%	18%	442	408	8%	13%
Other ¹	98	113	(13%)	(18%)	367	498	(26%)	(20%)
Total BioScience	\$1,518	\$1,359	12%	7%	\$5,573	\$5,308	5%	10%
Medication Delivery								
IV Therapies	\$438	\$393	11%	6%	\$1,562	\$1,575	(1%)	6%
Global Injectables	479	420	14%	9%	1,701	1,584	7%	12%
Infusion Systems	246	222	11%	7%	858	906	(5%)	(2%)
Anesthesia	140	131	7%	4%	492	464	6%	10%
Other	9	8	13%	25%	36	31	16%	6%
Total Medication Delivery	\$1,312	\$1,174	12%	7%	\$4,649	\$4,560	2%	7%
Renal								
PD Therapy	\$509	\$458	11%	5%	\$1,856	\$1,862	0%	5%
HD Therapy	116	99	17%	11%	410	444	(8%)	0%
Total Renal	\$625	\$557	12%	6%	\$2,266	\$2,306	(2%)	4%
Baxter excluding Transfusion Therapies	\$3,455	\$3,090	12%	7%	\$12,488	\$12,174	3%	7%
Transfusion Therapies ²	\$15	\$41	(63%)	(63%)	\$74	\$174	(57%)	(55%)
Total Baxter	\$3,470	\$3,131	11%	6%	\$12,562	\$12,348	2%	7%

¹ Principally includes vaccines and sales of plasma to third parties.

² Represents revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the TT business after the February 2007 divestiture.